Results 141 to 150 of about 92,115 (273)

Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer

, 2009
OBJECTIVE: \ud This study explored gene expression differences in predicting response to chemoradiotherapy in esophageal cancer. \ud \ud PURPOSE::\ud A major pathological response to neoadjuvant chemoradiation is observed in about 40% of esophageal ...
Maher, Stephen G., Duggan, Shane P., Sheils, Orla M., Miller, Nicola, O'Byrne, Kenneth J., Hollywood, Donal, Muldoon, Cian, Reynolds, John V., Gillham, Charles M., Smyth, Paul C.   +9 more
core   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

International Journal of Cancer, Volume 159, Issue 10, Page 2552-2561, 15 November 2026.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden, Tamara J. Huizer, Ben M. Eyck, Ate van der Gaast, Leni van Doorn, Marjolein Y. V. Homs, J. Jan B. van Lanschot, Joost J. M. E. Nuyttens, Lindsey Oudijk, Manon C. W. Spaander, Bas P. L. Wijnhoven, Bianca Mostert, Sjoerd M. Lagarde   +12 more
wiley   +1 more source

A randomized phase 3 trial of total neoadjuvant therapy (induction chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemotherapy, and surgery) vs. standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant chemotherapy) in locally advanced rectal cancer

Frontiers in Oncology
PurposeThe management of rectal adenocarcinoma has evolved during the last decade, shifting from a conventional neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy in all cases to a total neoadjuvant approach, especially in locally advanced
Freshte Foroughi, Seyed Alireza Javadinia, Roham Salek   +2 more
doaj   +1 more source

MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti‐MET Antibody‐Drug Conjugate Therapy

International Journal of Cancer, Volume 159, Issue 10, Page 2606-2618, 15 November 2026.
ABSTRACT MET is an actionable receptor tyrosine kinase, and MET‐directed antibody–drug conjugates (ADCs) have recently entered clinical practice with FDA approval in non‐small cell lung cancer and are now being evaluated across gastrointestinal malignancies, with patient selection based on MET immunohistochemistry (IHC) 3+ membranous staining at ...
Tillmann Bedau, Thomas Zander, Hans Anton Schlößer, Hakan Alakus, Onur Mustafov, Reinhard Büttner, Christiane Bruns, Alexander Quaas   +7 more
wiley   +1 more source

Neoadjuvant chemoradiotherapy with 5-fluorouracil by bolus.

Anticancer research, 2008
Neoadjuvant chemoradiotherapy (CT-RT) with continuous infusion (c.i.) 5-fluorouracil (5-FU) before resection of high-risk rectal cancer improves overall survival (OS) and pelvic control. Since the presence of cardiomiopathy may contraindicate c.i. of 5-FU, an alternative regimen of 5-FU CT-RT was prospectively studied in these patients.From October ...
Pasetto LM, Sinigaglia G, BASSO, UMBERTO, Cocchio S, Compostella A, PUCCIARELLI, SALVATORE, Friso ML, RUGGE, MASSIMO, Toppan P, Agostini M, MONFARDINI, SILVIO   +10 more
openaire   +2 more sources

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma

BMC Cancer
Background Neoadjuvant immune checkpoint blockade (ICB) combined with chemoradiotherapy offers high pathologic complete response (pCR) rate for patients with locally advanced esophageal squamous cell carcinomas (ESCC).
Dan-Dan Zheng, Yu-Ying Li, Xiao-Yi Yuan, Jiang-Li Lu, Mei-Fang Zhang, Jia Fu, Chris Zhiyi Zhang   +6 more
doaj   +1 more source

P1.194. Timing of Esophagectomy After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Topic Esophageal Cancer: Surgical Treatment of Esophageal Cancer – early outcomes and complications Background The optimal interval between neoadjuvant ...
Aravind Sekar, Satish Nagaraj, CHERRING TANDUP, Jayanta Samanta, Swapnesh Sahu, Lovepreet Singh, Manish Thakur   +6 more
core   +1 more source

Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review

Aging and Cancer, Volume 7, Issue 3, Page 125-141, September 2026.
This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel, S. Tissera, E. Paul, J. Zalcberg, R. G. Stirling   +4 more
wiley   +1 more source

Therapiestrategien für das Ösophaguskarzinom [PDF]

, 2012
Wolf, Maria
core   +1 more source